Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study

• Published in: Nagoya journal of medical science Vol. 81; no. 3; pp. 359 - 373
• Main Authors: Senda, Joe, Ito, Keiichi, Kotake, Tomomitsu, Kanamori, Masahiko, Kishimoto, Hideo, Kadono, Izumi, Nakagawa-Senda, Hiroko, Wakai, Kenji, Katsuno, Masahisa, Nishida, Yoshihiro, Ishiguro, Naoki, Sobue, Gen
• Format: Journal Article
• Language: English
• Published: Japan Nagoya University 01.08.2019
• Subjects: Activities of Daily Living; Aged; Aged, 80 and over; Cilostazol - therapeutic use; Female; Humans; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Original Paper; Recovery of Function - physiology; Rehabilitation Centers; Retrospective Studies; Stroke Rehabilitation - methods; Treatment Outcome; Cilostazol; convalescent rehabilitation; FIM cognitive; ischemic stroke
• ISSN: 0027-7622; 2186-3326
• DOI: 10.18999/nagjms.81.3.359

Cilostazol is a phosphodiesterase III-inhibiting antiplatelet agent that is often used to prevent stroke and peripheral artery disease, and its administration has shown significant improvements for cognitive impairment. We investigate the potential of cilostazol for reducing or restoring cognitive decline during convalescent rehabilitation in patients with non-cardioembolic ischemic stroke. The study sample included 371 consecutive patients with lacunar (n = 44) and atherothrombosis (n = 327) subtypes of non-cardioembolic ischemic stroke (224 men and 147 women; mean age, 72.9 ± 8.1 years) who were required for inpatient convalescent rehabilitation. Their medical records were retrospectively surveyed to identify those who had received cilostazol (n = 101). Patients were grouped based on cilostazol condition, and Functional Independence Measure (FIM) scores (total and motor or cognitive subtest scores) were assessed both at admission and discharge. The gain and efficiency in FIM cognitive scores from admission to discharge were significantly higher in patients who received cilostazol than those who did not (p = 0.047 and p = 0.035, respectively); we found no significant differences in other clinical factors or scores. Multiple linear regression analysis confirmed that cilostazol was a significant factor in FIM cognitive scores at discharge (β = 0.041, B = 0.682, p = 0.045); the two tested dosages were not significantly different (100 mg/day, n = 43; 200 mg/day, n = 58). Cilostazol can potentially improve cognitive function during convalescent rehabilitation of patients with non-cardioembolic ischemic stroke, although another research must be needed to confirm this potential.